Loading
Macrogenics Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 21 Aug 2025.
Macrogenics Inc: what insiders have been doing
Macrogenics Inc is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). The last twelve months, up to 18 October 2026, brought 22 filings signed by 10 insiders.
All open-market trades in the period are sales: 1 sale worth €111k, by 1 insider, with no purchase on record. The largest single trade was a sale of €111k by Peters Jeffrey Stuart, published on 20 August 2026, equal to 0.053% of the market capitalisation.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 22 filings, this issuer sits right on that mark. Over the whole record (from 2016), the tally stands at 17 purchases and 9 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 149.5 m USD and net income at -74.6 m USD.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
120
Thresholds
n/a
Buy Volume
€26M
17 ops. · all time
Sell Volume
€2M
9 ops. · all time
Who traded when
BuySaleJeffrey Stuart Peters1 sale
William K. Heiden1 buy
Since the insiders bought
- +137.9%Entry US$1.69 · Close at T+365 US$4.02
- -24.9%Entry US$4.78 · Close at T+365 US$3.59
- -35.4%Entry US$5.08 · Close at T+365 US$3.28
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,520 of 24,158 companies
18.4
score / 100
Value6
Quality31
FCF yld-40%
Earn yld-36%
EV/EBITDA·
ROE-226%
Gross mgn76%
Net mgn-50%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.25
Analyst consensus
4 analysts2.29/5
US$4.00Target US$8.00(+146%)US$11.00
Income statement
RevenueUS$149.5M
Gross profitUS$113.5M76% margin
EBITDA-US$59.6M-40% margin
Net income-US$74.6M-8.3% margin
Valuation
PER (forward)-2.2x
P/Book4.8x
Beta1.21
Balance sheet & cash
Market capUS$207M
Total debtUS$36.8M
Free Cash Flow-US$83M
Debt / Equity82%
Profitability & ownership
ROE-225.8%
ROA-8.1%
% insiders3.5%
% institutions76.4%
Last declaration on 7 October 2026
Declarations120 total
8,000 shares@ US$2.600.0081% mcap1.9% of flowCommon StockSEC:0001125345-26-000063:0
15,811 shares@ US$4.1446100.0% of flowCommonSEC144:0001628280-26-062884
31,105 shares@ US$4.150.053% mcap8.7% of flowCommon StockSEC:0001706903-26-000006:0
31,105 shares@ US$4.1519100.0% of flowCommonSEC144:0001628280-26-058022
40,000 shares@ US$2.600.043% mcap9.2% of flowCommon StockSEC:0001588365-26-000007:0
42,080 shares@ US$4.17530.071% mcap57.2% of flowCommonSEC144:0001628280-26-057456
34,916 shares@ US$3.750.053% mcap42.8% of flowCommonSEC144:0001628280-26-051901
17,000 shares@ US$4.44290.031% mcap100.0% of flowCommonSEC144:0001628280-26-048068
21,165 shares0Common StockSEC:0001587514-26-000007:0
1,095 sharesCommon StockSEC:0002051299-26-000005:0
13,332 sharesCommon StockSEC:0001706903-26-000004:0
13,332 sharesCommon StockSEC:0001675464-26-000004:0
16,665 sharesCommon StockSEC:0001588365-26-000005:0
16,665 sharesCommon StockSEC:0001587774-26-000004:0
14,999 sharesCommon StockSEC:0001587477-26-000005:0
7,001 sharesCommon StockSEC:0001588365-26-000002:0
6,668 sharesCommon StockSEC:0001587774-26-000002:0
15,831 sharesCommon StockSEC:0001587514-26-000004:0
6,334 sharesCommon StockSEC:0001587477-26-000002:0
2,617 sharesCommon StockSEC:0002051299-26-000002:0
6,001 sharesCommon StockSEC:0001706903-26-000002:0
6,001 sharesCommon StockSEC:0001675464-26-000002:0
50,500 shares@ US$1.52100.0% of flowCommon StockSEC:0001214939-25-000004:0
Canonical exit: 17 Nov 2025 (T+90)
21,165 shares0Common StockSEC:0001587514-25-000005:0
6,500 sharesCommon StockSEC:0001125345-25-000081:0
25 of 120 declarations
About Macrogenics Inc
MacroGenics Inc. (NASDAQ: MGNX) is a United States-based biopharmaceutical company headquartered in Rockville, Maryland, and listed on the NASDAQ market. For French-speaking investors, it is best understood as a clinical-stage oncology biotech focused on the discovery and development of innovative antibody-based therapeutics. The company was founded in the early 2000s and has built its identity around proprietary antibody-engineering capabilities that support both an internal pipeline of drug candidates and a network of strategic collaborations with larger pharmaceutical partners.
MacroGenics’ business model is built on three complementary revenue and value-creation engines: advancing in-house clinical programs, monetizing technology through partnerships and licensing arrangements, and selectively divesting assets when management believes capital can be redeployed more efficiently. Historically, the company commercialized MARGENZA, an approved HER2-directed monoclonal antibody for metastatic HER2-positive breast cancer. However, the global rights to MARGENZA were sold to TerSera Therapeutics, which materially shifted the company’s emphasis back toward its proprietary pipeline and longer-duration oncology opportunities.
Read moreShow less
From a competitive standpoint, MacroGenics operates in a highly specialized biotech niche where scientific differentiation matters more than near-term scale. Its technology platforms are designed to generate next-generation antibody therapies, including T-cell engager programs and antibody-drug conjugates (ADCs), with oncology remaining the core therapeutic area. Recent company communications have highlighted programs such as lorigerlimab, MGC026, and MGC028, along with additional preclinical or clinical assets. In practice, MacroGenics competes on the strength of its platform science, clinical data, and ability to secure external capital and partner support, rather than on commercial breadth.
Geographically, the company’s footprint remains primarily U.S.-centric, with core operations in Maryland and a broader international presence mainly through global collaboration agreements rather than direct large-scale commercialization. That is typical for a research-driven biotech that is still in the value-creation phase. The company’s business development strategy also reflects this structure, as partnerships can provide non-dilutive funding and de-risk portions of the pipeline.
Recent notable developments in 2025 and 2026 include pipeline prioritization changes, continued advancement of selected clinical programs, partnering transactions that generated additional proceeds, and cost/cash-runway measures intended to extend financial flexibility. The company’s recent SEC Form 4 insider transaction filings also indicate ongoing market interest in management and insider activity, which investors often monitor closely in the U.S. biotech sector.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
